Eavesdropping in the Exam Room: Should States Regulate Prescription Data Mining?

Cindy Rosenwald
State Representative
New Hampshire
August 6, 2007

Prescription Data Mining

- What is it?
  - Computer database technology introduced 1993
  - Tracks drug prescriptions written by individual prescribers by specific brand
  - Sold to drug companies to target marketing to doctors as individuals
- Why should states consider regulation?
  - Cost
  - Privacy
  - Health Care Quality
Clash of Values

- Drug company goals are revenue, share, and profit
- Public policy goals are affordable, safe, high quality health care
- Information has economic value

Rx Drug Costs Rising Dramatically

- Fastest growth among all sectors
  - Up 74% over 5 years in New Hampshire
  - Public and private spending impact
  - $868 per capita
  - Projected 47% increase next 5 years
  - Medicaid Rx costs higher than hospitals and doctors combined, up 68% in 5 years
  - Prisoner Rx costs higher than hospitals, doctors, and diagnostics combined
Marketing RX Drugs

- Billions spent marketing to doctors and patients
- One third of revenue spent on marketing
  - $5 billion spent on consumer advertising
  - $15 billion spent on free samples and marketing to doctors, $15,000 per physician
  - 90,000 sales reps; 1 for every 5 doctors
  - Breakeven for one sales call is one new prescription
  - Data mining industry is a $2 billion convenience to pharmaceutical industry

Quality of Care Depends on Trust and Objectivity

- Drug companies have unauthorized access to private relationship
- Patient/Doctor relationship is complex
  - Like a drug rep listening at the door
  - Ability to influence private relationship between doctor and patient
  - Best care combines professional judgment with personal knowledge and patient’s interest, not commercial interests
Patient Identity

- Industry denies knowledge of patient identity
  - Incomplete compliance testimony
  - Direct mail advertising to patients
- Concerns about electronic vendor privacy standards
- Concerns about HIPAA

Prescriber Data Mining Regulation

- NH law prohibits commercial use of prescriber identity
  - Allows collection, non-commercial use
  - Allows aggregate data commercial usage
  - Enjoined by federal district court decision, on appeal
- Vermont enacts opt-in, Maine enacts opt-out
- AMA has voluntary opt-out program
  - Drug companies still see prescribing records even when doctors opt out
  - AMA has multi-million $ conflict of interest
  - 8,000 doctors (1%) have signed up
  - Majority of physicians support data mining ban
Pharmaceutical Industry Opposition

- Contention: Physician tracking saves money
  - “Makes marketing more efficient”
  - Which doctors should get samples

- Reality: It contributes to spending growth
  - Marketing and sampling are for expensive brand name drugs, not cheaper generics
  - $2 billion data mining cost passed on to consumers and payers
  - Practice level aggregate data is enough

Pharmaceutical Industry Opposition

- Contention: Physician tracking improves care
  - Sales reps can teach doctors how to use drugs
  - Contributes to health research
  - Doctors are sophisticated, not subject to influence of marketing, sales reps

- Reality: Marketing does not improve care
  - Sales reps not qualified to teach doctors
  - Research not impacted by regulations
  - Studies show gifts change prescribing habits, create sense of obligation
Pharmaceutical Industry Opposition

- Contention: Physician tracking improves safety
  - Can help with FDA programs to warn prescribers and patients of safety problems
    - Recalls
    - Black box warnings
    - Risk management / special prescribing qualifications
    - Adverse event reporting
    - Find doctors who prescribe inappropriately
  - Warnings should be targeted

Pharmaceutical Industry Opposition

- Reality: Safety programs must—and do—cast broader net
  - FDA is silent on data mining
  - Many ways to report problems to doctors
  - Warnings must reach all potential prescribers
    - Toe nail fungus warning to psychiatrists
  - Doctors report adverse events to FDA
  - Warnings can be linked to e-prescribing
  - Better ways to monitor prescription fraud/abuse
  - Safety efforts not prohibited by legislation
What Does the Future Hold?

- More data will be available electronically
- Data has enormous value
- Public policy must weigh cost, privacy, quality

Contact Information

Representative Cindy Rosenwald, Chairman
Health, Human Services, and Elderly Affairs Committee
Legislative Office Building, Room 205A
33 North State Street
Concord, NH 03301
603.271.3580 (office)
603.595.9896 (home)
Cindy.Rosenwald@leg.state.nh.us